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Efficacy of Flow- vs Impedance-Guided
Autoadjustable Continuous Positive
Airway Pressure*
A Randomized Cross-over Trial
Dirk A. Pevernagie, MD, PhD; Pascal M. Proot, MD;
Katrien B. Hertegonne, MD; Marleen C. Neyens; Kristien P. Hoornaert, MD; and
Romain A. Pauwels, MD, PhD, FCCP
Study objectives: Autoadjustable continuous positive airway pressure (CPAP) devices are increas-
ingly used in the treatment of obstructive sleep apnea (OSA). Since different measurements of
upper airway obstruction are applied, it is uncertain whether these devices are equally effective
in controlling sleep-disordered breathing. Hypothesizing that differences in therapeutic efficacy
were to come out, we compared the performance of the AutoSet device (ResMed; Sydney,
Australia), which features autoadjustable positive airway pressure (APAP) guided by detection of
flow limitation (APAPfl), with the SOMNOsmart device (Weinmann; Hamburg, Germany), which
features APAP guided by the forced oscillation technique (APAPfot).
Design: A double-blind, randomized, cross-over trial.
Setting: The sleep disorders center and sleep laboratory of a university hospital.
Patients and interventions: An overnight CPAP autotitration procedure was performed in 30
patients with OSA. A split-night protocol allowed that each patient used both devices.
Measurements and results: Using polysomnography, sleep, indexes of sleep-disordered breathing,
snoring, and CPAP levels were recorded. No significant differences were found in conventional
sleep variables. While the apnea-hypopnea index (AHI) was lower with APAPfl (3.5  5.6/h) as
compared to APAPfot (9.9  31.0/h), the difference was not statistically significant (mean  SD).
The snoring index, however, was significantly lower with APAPfl (35.3  53.7/h vs 111.6  175.4/
h, respectively; p  0.01). The median and 95th percentile pressure levels rose from wakefulness
to sleep in APAPfl, but decreased in APAPfot. Higher pressure variability was present in the latter
method.
Conclusions: These findings suggest that the APAPfl is superior to APAPfot in the control of
snoring. While a lower AHI was achieved with APAPfl, at the expense of a higher median pressure
but less pressure variability, the difference with APAPfot was not statistically significant.
(CHEST 2004; 126:25–30)
Key words: AutoSet; continuous positive airway pressure; obstructive sleep apnea; snoring; SOMNOsmart
Abbreviations: AHI  apnea-hypopnea index; AI  arousal index; APAP  autoadjustable positive airway pressure;
APAPfl  autoadjustable positive airway pressure guided by detection of flow limitation; APAPfot autoadjustable
positive airway pressure guided by the forced oscillation technique; CPAP  continuous positive airway pressure;
OSA  obstructive sleep apnea; P50  median positive airway pressure; P95  95th percentile of positive airway
pressure
F or  2 decades, nasal continuous positive airwaypressure (CPAP) has been the cornerstone in the
treatment of patients with moderate-to-severe ob-
structive sleep apnea (OSA).1 Over the years, the
therapeutic end points of CPAP application have
evolved from abolishing respiratory events, including
apneas, hypopneas, and snoring, to controlling respi-
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ratory event-related arousals, and finally to normal-
ize airflow and respiratory effort.2
Most commonly, for treatment of OSA, based on
results of a formal sleep study, a fixed positive
pressure level is established by means of manual
pressure titration. However, the efficacy of this
method is uncertain because manual titration meth-
ods have never been standardized. Furthermore,
overnight CPAP requirements may be quite variable
due to a variety of reasons, such as changes in body
position and sleep stage,3 and consumption of alco-
holic beverages.
In more recent years, new devices have been
developed that are designed to deliver autoadjust-
able positive airway pressure (APAP), meeting the
patient’s immediate pressure needs.4 These devices
have the theoretical advantage of stabilizing the
upper airway during changing physiologic condi-
tions, thereby circumventing the methodologic is-
sues of manual pressure titration.
Although commercially available APAP devices
have been shown to be useful in the assessment of
CPAP requirements both in the sleep laboratory and
at home,5 it is still unknown whether the implicated
APAP technologies are equally effective.6 It has been
shown that devices that run on different pressure-
driving algorithms respond differently to changing
pressure demands.7 Therefore, we hypothesized that
differences in the ability of various devices to stabi-
lize sleep-disordered breathing should likewise oc-
cur. We compared two devices whose operation is
based on different modes of sensing incipient upper
airway obstruction. The operational characteristics of
the AutoSet device (ResMed; Sydney, Australia)
feature APAP guided by detection of flow limitation
(APAPfl) of inspired air and the subsequent pressure
adaptation.8 The SOMNOsmart device (Weinmann,
Hamburg, Germany) features APAP guided by the
forced oscillation technique (APAPfot).9 Pressure
adjustments are based on changes in the measured
impedance, and aim at keeping the resistance below
a given percentage of wakefulness values. Favorable
outcomes have been reported on the use of both
aforementioned APAP devices regarding pressure
titration in the sleep laboratory,9–14 as well as unat-
tended use in the home environment.15,16 The
present study was designed to compare the efficacy
of these two APAP technologies in terms of effects
on sleep quality, respiratory disturbance, and snoring
indexes. Since adequate control of sleep-disordered
breathing should be achieved at the lowest possible
pressure level, it was also evaluated if the pressure
output was appropriate in terms of magnitude and
variability.
Materials and Methods
Subjects
Patients who demonstrated an apnea-hypopnea index (AHI)
 20/h plus an arousal index (AI)  30/h (ie, Belgian criteria for
reimbursement of nasal CPAP) were enrolled. Exclusion criteria
included a history of prior uvulopalatopharyngoplasty, signs of
severe nasal obstruction, excessive sleep disruption due to non-
respiratory causes, and COPD (ie, FEV1/FVC  65%). None of
the patients had symptoms and signs of congestive heart failure.
No one refused to enter the study. Five patients had to be
excluded after the registration because of intolerance or technical
problems. Twenty-seven male and 3 females subjects (mean age,
53.8  10.1 years; body mass index, 30.5 4.5; FEV1/FVC,
0.76  0.06; AHI, 52.9  27.2/h; AI, 50.4  19.8/h) successfully
completed the study ( SD). The study ran from January 2001
until July 2001. The participants gave written informed consent,
and the trial was approved by the Ethical Review Board of our
institution.
Sleep Studies
Polysomnography was carried out using a 19-channel digital
polygraph (Morpheus; Medatec; Brussels, Belgium). A standard-
ized sleep recording procedure was carried out, as previously
described.17 To record airflow, thermocouples plus nasal pres-
sure cannulae were used during baseline studies. During the
APAP trial, airflow was evaluated by measuring the respiratory
pressure fluctuations in the nasal mask, which was connected via
4-mm-diameter flexible tubing to the built-in manometer (model
164PC01D37; Honeywell; Freeport, IL). Respiratory movements
were recorded using thoracic and abdominal piezo-sensors
(Sleepmate Technologies; Midlothian, VA). Sleep and respiratory
events were manually scored in epochs of 30 s. Sleep stages were
identified according to standard criteria.18 The scoring of arousals
was based on published guidelines.19 The AI, the AHI, and the
snoring index (ie, count of inspiratory snores per hour of sleep)
were assessed according to previously described methods.17 The
CPAP level was also assessed manually in epochs of 30 s. A
pressure value and corresponding sleep stage were allocated to
each epoch.
Trial Protocol
Before carrying out a CPAP titration procedure, the patients
were habituated on fixed CPAP home treatment. The CPAP was
empirically set at a predicted pressure value of 7.9 1.8 cm
H2O.20 The CPAP compliance before the titration study was
4.7  2.5 h/night. The CPAP habituation period was 90.5  69.2
days. The patients were subsequently hospitalized to carry out an
overnight study in which the AutoSet and SOMNOsmart devices
were used in randomized order. The devices were covered in
identical boxes for blinding purposes. After 4 h, the mask was
disconnected from the first device and attached to the next
device, which was then used for another 4 h. Both devices were
programmed to a pressure range between 4 cm H2O and 14 cm
H2O. The APAP devices were compared regarding their effect on
relevant sleep and respiratory variables. The median positive
airway pressure (P50) and 95th percentile of positive airway
pressure (P95) values were computed differentially for the states
of sleep and wakefulness. Finally, the P50/P95 ratio was calcu-
lated. The lower the index, the greater the difference between
P50 and P95, which is indicative of increased pressure variability.4
Scoring was done by one skilled technician, and reviewed by the
first author of this article. Both were blinded to the treatment
conditions.
26 Clinical Investigations
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Statistical Analysis
The paired t test was applied for evaluating differences be-
tween treatment conditions. To analyze whether the APAP
devices behave differently in the sleep vs wake state, analysis of
variance for repeated measurements was applied. This statistical
procedure can be used to evaluate the interaction between
different predictor variables (ie, the treatment condition and the
sleep vs wake state) on therapeutic outcome (ie, pressure level).
SPSS version 11.0 statistical software was used (SPSS; Chicago,
IL). All presented data are mean  SD unless otherwise
specified.
Results
Comparison of the two APAP devices showed no
significant differences in the various sleep parame-
ters, including time in bed, total sleep time, sleep
efficiency, sleep stages, and AI (Table 1). While the
AHI was lower with the use of APAPfl (3.5  5.6/h)
as compared to APAPfot (9.9  31.0/h), the differ-
ence was not statistically significant (p  0.27). In
contrast, the snoring index was significantly lower
with the application of APAPfl in comparison with
APAPfot (35.3  53.7/h vs 111.6  175.4/h, respec-
tively; p  0.01). Analysis of variance for repeated
measurements showed a highly significant interac-
tion between the treatment condition (APAPfl vs
APAPfot) and the sleep vs waking condition with
respect to pressure output (p 0.004). While P50
and P95 were significantly higher during sleep with
APAPfl as compared with APAPfot, both variables
rose from wakefulness to sleep in APAPfl, but
decreased in APAPfot (Fig 1). During sleep, the
P50/P95 was significantly lower with APAPfot as
compared with APAPfl (0.65 0.15 vs 0.79 0.11,
respectively; p  0.001), indicating increased pres-
sure variability in the former method. A typical
example of pressure variability in a patient is shown
in Figure 2.
Discussion
The present study is one of the first clinical reports
to compare the efficacy of two devices that are
driven by different mechanisms for detection of
upper airway obstruction. In this double-blind, ran-
domized, cross-over trial, APAPfl (AutoSet device)
and APAPfot (SOMNOsmart device) methods were
compared. APAPfl provided a significantly better
control of snoring, and resulted in a lower AHI
(though not significantly) than APAPfot. These dif-
ferences in respiratory parameters were best ex-
plained by differences in pressure profiles of the two
devices. The median and 95th percentile of pressure
levels rose significantly from wakefulness to sleep
when using APAPfl, but fell paradoxically in the
APAPfot treatment arm. In addition, APAPfot was
Table 1—Sleep Parameters in Both Treatment
Conditions*
Parameters APAPfl APAPfot
Time in bed, min 238 36 228  41
TST, min 180  41 177  53
Sleep efficiency, % 76 16 77  17
Wakefulness, min 58  45 53  38
NREM stage 1, min
(% TST)
21  14 (13  9) 20  15 (13  9)
NREM stage 2, min
(% TST)
103  37 (65  23) 98  33 (62  21)
NREM stage 3–4, min
(% TST)
19  21 (12  13) 17  17 (10  11)
REM sleep, min (%
TST)
40  23 (25  14) 37  27 (23  17)
AI, events/h 3  3 9  24
*Data are presented as mean  SD. The paired t test showed no
significant differences between APAPfl and APAPfot methods in
any of the listed variables. NREM  non-rapid eye movement;
REM  rapid eye movement; TST  total sleep time.
Figure 1. Changes of pressure output in APAPfl (AutoSet device) [white bars] as compared with
APAPfot (SOMNOsmart device) [black bars] from wakefulness (W) to sleep (S). *p  0.05;
***p  0.001. The error bars represent SEM. P50 and P95 are significantly higher during sleep with
APAPfl as compared with APAPfot. P50 and P95 increase from wakefulness to sleep in APAPfl. The
opposite is true with APAPfot.
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subject to significantly higher pressure variability,
which was indicated by a lower P50/P95 ratio.
Both the measurement of respiratory impedance
based on forced oscillations applied to the upper
airway, and the detection of inspiratory flow limita-
tion have been used for monitoring of residual airway
obstruction during CPAP titration. Lorino et al21
demonstrated that the former method is more sen-
sitive than the latter. Accordingly, the responses to
the detection of disturbed breathing may be differ-
ent in APAPfot and APAPfl methods. Another im-
portant difference between the two methods are the
reaction times (change in pressure/change in time)
that determine the rate at which the pressure adjust-
ment will be completed. The slope of adaptation is
steeper in both lowering and increasing the pressure
in response to certain respiratory events with the
APAPfot method. While a more sensitive and faster
response to respiratory changes may predispose the
APAPfot method to greater variability in pressure
output, the handling of unphysiologic signals by the
APAPfot method is also dissimilar from the APAPfl
method. The AutoSet device, in contrast to the
SOMNOsmart device, has a built-in system for the
Figure 2. Split-night trends showing the effects of both APAP methods in a typical patient. Top panel:
hypnogram (A awake; R  rapid eye movement sleep; 1 to 4 NREM stages 1 to 4). Second panel:
oxyhemoglobin concentration (Spo2) measured with a pulse oximeter. Middle panel: occurrence of
disturbed respiratory (RESP) events (ObsA  obstructive apnea; Hpop  hypopnea). Fourth panel:
snoring sound measured with a microphone (PHONO) at the level of the larynx. Bottom panel: pressure
trends of APAPfl and APAPfot. Note the increased pressure and limited pressure swings in APAPfl
(P50/P95  0.90). In contrast, APAPfot shows large pressure swings and failure to increase baseline
pressure during episodes of loud snoring (P50/P95  0.38).
28 Clinical Investigations
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continuous monitoring of bias flow. The system is
able to compensate for pressure drops due to exces-
sive air leakage up to a flow rate of 0.4 L/s.11 Since
mask and/or mouth leaks often occur during sleep,
this may in part explain why higher median positive
pressure levels were found in the AutoSet device.
The pressure data from the present trial corre-
spond to previously published results. The mean
pressure values in a report9 on the SOMNOsmart
device are similar to our current findings. In that
study, Randerath et al9 reported that the SOM-
NOsmart device produced significantly lower pres-
sure values in comparison with a manual titration
procedure. As in our study, snoring was not elimi-
nated in the APAPfl arm of the trial. Moreover, the
P50 and P95 values of the AutoSet device are quite
similar to previously published data on patients with
a comparable severity of OSA and body mass index.15
Since it is known that the pressure required to
abolish snoring exceeds the pressure required to
eliminate apneas by 2 cm H2O in  90% of the
patients,22 it is evident that the better control of
snoring obtained with APAPfl in this study is ex-
plained by the median CPAP level, which was on
average 2.5 cm H2O higher than the median pres-
sure produced by the APAPfot method.
From the present study, several issues emerge
regarding our understanding of the operational fea-
tures of APAP technology. The observation that the
AHI, the principle outcome measure of this study,
was not significantly different in two devices with
markedly different pressure profiles requires further
consideration. We hypothesize that there is a margin
of pressure tolerance around an optimal CPAP level
in a given patient at a given time. While obstructive
breathing events will reappear when the pressure is
reduced below a critical lower limit, raising the
pressure above an upper threshold will induce air
leakage and bring on unwarranted side effects. While
essentially no data on the hypothetical upper pres-
sure limit exist, it is known from the literature that
“sham” nasal CPAP levels as low as 2 cm H2O may
induce significant improvements in markers of sleep-
disordered breathing.23 Hence, the corresponding
margin of pressure tolerance may comprise several
centimeters of water. Within this conceptual margin,
however, pressure adjustments will not appreciably
affect sleep or breathing outcomes. We believe that
the two APAP devices under study operated to a
large extent in the presumed zone of pressure toler-
ance, which provides an explanation for the absence
of a significant difference in effect on the AHI. Also
in this concept, the absence of residual disturbed
breathing at a given CPAP level does not by itself
mean that this is the result of appropriate pressure
adaptation. Second, it is unclear whether one mea-
sure of upper airway narrowing is sufficient to
reliably titrate CPAP. It has been suggested that
obstructive breathing events identified by the forced
oscillation technique should not be scored unless
corroborated by the concurrent presence of im-
paired ventilation, which requires the use of a pneu-
motachograph.4,24 Improved results, ie, normaliza-
tion of the AHI at lower and more stable CPAP
levels, might be obtained from the combined use of
both techniques. Third, knowledge regarding the
appropriate rate of pressure adjustment is lacking.
From the present study it is clear that a fast pressure
response is not necessarily synonymous with im-
proved stabilization of breathing. On the contrary,
excessive pressure variability may lead to inadequate
control of snoring and sleep-disordered breathing.
In conclusion, the results of the present study
show that a significantly better suppression of snor-
ing is achieved by APAPfl than with APAPfot. Fur-
thermore, AHI was lower with APAPfl than with
APAPfot, although this difference was not statisti-
cally significant. The pressure profile of AutoSet
device was strikingly different from the SOM-
NOsmart device in that AutoSet device had a higher
median pressure but less pressure variability than the
SOMNOsmart device. The difference in pressure
profile best explains the differences in snoring and
AHI observed with these two devices.
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